A news article about a randomized clinical trial testing a common antidepressant as a potential treatment for long COVID fatigue, inviting readers curious about emerging therapeutic research.
Key Takeaways
- Randomized clinical trial enrolled 399 adults to test fluvoxamine for long COVID fatigue
- Fluvoxamine significantly reduced fatigue compared with placebo in the trial cohort
- Participants receiving fluvoxamine reported improved quality of life versus placebo